about
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyImmune Checkpoint in Glioblastoma: Promising and ChallengingNivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma.Checkpoint inhibitors in immunotherapy of ovarian cancer.From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment.Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.Patent trend and competitive analysis of cancer immunotherapy in the United States.Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients.Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review.HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy.Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
P2860
Q26823515-0C5D9919-C380-444A-AA83-AF77D75A03A5Q33650058-39F42CB5-DCA9-4450-9A2F-B4B8A0A764B0Q37264931-694C1440-E926-4F71-A71D-0606AF56362BQ37457628-C1159F65-984C-4BCB-AE1A-96861D3C2D56Q37588227-F69CE8E8-D917-44FD-9170-1EFD9D9C3032Q38269568-A002F685-E0E3-4B3B-B3AC-06E9C8FB09CDQ38468283-3915BB81-0817-4A6C-959D-D66B69CAEE20Q38806038-8F4DB400-1CC2-47EE-B9BE-40DA3B31EA6DQ40517920-271E013B-B545-47B1-A3DA-3E3B4A4EA445Q41078784-E9E16B2E-EE7D-4033-ACD5-A3340571B631Q41708775-1DD80EC9-F638-4DE1-888C-0BD6A3785371Q41967898-4B146BFD-FC6C-4EC3-B302-68D19441ED46Q46310803-B448339E-D007-436D-A257-5CC30A102F34Q47094138-49FC4D6D-9FB3-43FC-BA7E-5D809A958B95Q47151168-A3C3461F-52EF-4EB5-B752-45AC09DA5E48Q47296036-4E380543-AD84-4E5B-A5BD-EC318DBA44ADQ47826173-72498FDB-93E4-4585-953B-9D51D40B7CF9Q49463699-F87F81AB-4C53-4303-8851-2798BA99E660Q50104904-1106FF6F-94CD-4FEB-8430-4A53319DB629Q52560940-81B1CA4B-E9B3-4436-A7F7-D7B343E541D9Q58766967-2B0617F8-D900-425A-B65C-AD4556CFFBD4
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Immune checkpoint inhibitors in clinical trials
@ast
Immune checkpoint inhibitors in clinical trials
@en
Immune checkpoint inhibitors in clinical trials
@nl
type
label
Immune checkpoint inhibitors in clinical trials
@ast
Immune checkpoint inhibitors in clinical trials
@en
Immune checkpoint inhibitors in clinical trials
@nl
prefLabel
Immune checkpoint inhibitors in clinical trials
@ast
Immune checkpoint inhibitors in clinical trials
@en
Immune checkpoint inhibitors in clinical trials
@nl
P2093
P2860
P356
P1476
Immune checkpoint inhibitors in clinical trials
@en
P2093
Elad Sharon
Helen X Chen
Howard Streicher
Priscila Goncalves
P2860
P304
P356
10.5732/CJC.014.10122
P577
2014-09-01T00:00:00Z